About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/10/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/10/2020.

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Clinicaltrials.gov identifier NCT03952039

Recruitment Status Recruiting

First Posted May 16, 2019

Last update posted April 7, 2020

Study Description

Brief summary:

A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms.

  • Condition or Disease:Primary Myelofibrosis
    Post-Polycythemia Vera
    Myelofibrosis
  • Intervention/Treatment: Drug: FEDRATINIB
    Drug: Best Available Therapy (BAT)
  • Phase: Phase 3
Detailed Description

This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF). This study will be conducted in compliance with International Council for Harmonisation (ICH) Good Clinical Practices (GCPs). Study design includes: - A 28-day Screening Period - 2:1 Randomization to fedratinib or best available therapy (BAT) - Stratification at Randomization according to: - Spleen size by palpation: < 15 cm below left costal margin (LCM) versus ≥ 15 cm below LCM - Platelets ≥ 50 to < 100 x 109/L versus platelets ≥ 100 x 109/L - Refractory or relapsed to ruxolitinib treatment versus intolerant to ruxolitinib treatment - Study Treatment Period (time on study drug plus 30 days after last dose) - Subjects are allowed to crossover from BAT to the fedratinib arm after the Cycle 6 response assessment or before the Cycle 6 response assessment in the event of a confirmed progression of splenomegaly by MRI/CT scan - A Survival Follow-up Period for progression and survival

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 192 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib
  • Actual Study Start Date: September 2019
  • Estimated Primary Completion Date: November 2021
  • Estimated Study Completion Date: May 2025
Arms and interventions
Arm Intervention/treatment
Experimental: Fedratinib 400mg/day
Will include up to 128 subjects receiving fedratinib 400 mg self-administered Investigational Product (IP) on an outpatient basis, once daily preferably together with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
Drug: FEDRATINIB
A potent and selective inhibitor of JAK2 kinase activity
Active Comparator: Best Available Therapy (BAT)
Best-available Investigator-selected therapy included a number of available compounds to treat MF and/or its symptoms and was chosen by the investigator for each subject. Therapy changed at different times during the treatment period. No investigational agents (e.g. not approved for the treatment of any indication) were allowed. BAT also included the choice of no treatment.
Drug: Best Available Therapy (BAT)
Best available therapy (BAT)
Outcome Measures
  • Primary Outcome Measures: 1. Proportion of subjects who have ≥ 35% SVR at end of cycle 6 [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Spleen volume response rate (RR)
  • Secondary Outcome Measures: 1. Durability of Spleen Volume Response by MRI/CT (DR) [ Time Frame: Up to end of Cycle 6 (each cycle is 28 days) ]
    Is defined as time from the first documented spleen response (ie, ≥ 35% reduction in spleen volume) to the first documented spleen volume reduction < 35%.
  • 2. Proportion of subjects with ≥ 50% reduction in total symptom scores measured by MFSAF at end of cycle 6 [ Time Frame: Up to end of Cycle 6 (each cycle is 28 days) ]
    Symptom response rate (SRR)
  • 3. Proportion of subjects who have ≥ 25% reduction in spleen volume at the end of cycle 6 [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Spleen volume response rate (RR25)
  • 4. Adverse Events (AEs) [ Time Frame: Up to 30 days post last dose ]
    Number of participants with adverse event
  • 5. Proportion of subjects who have ≥ 50% reduction in spleen size by palpation at end of cycle 6 [ Time Frame: Up to end of Cycle 6 (each cycle is 28 days) ]
    Spleen response rate by palpation (RRP)
  • 6. Duration of ≥ 50 % reduction in spleen size by palpation for subjects with a palpable spleen at least 5 cm below the left costal margin (LCM) at baseline [ Time Frame: Up to approximately 30 months ]
    From C1D1 until the 30- day follow-up after last dose visit
  • 7. Duration of ≥ 50% reduction in total symptom scores measured by MFSAF [ Time Frame: From enrollment until 30 days post last dose ]
    Durability of symptoms response (DSR)
  • 8. Time from randomization to death due to any reason or disease progression (modified IWG-MRT 2013 including ≥ 25% increase in spleen volume by MRI/CT) [ Time Frame: Up to 24 months from enrollment to End of Survival Follow-up ]
    Spleen and disease progression free survival (SDPFS)
  • 9. Gastrointestinal Adverse Events [ Time Frame: Up to approximately 30 months ]
    Incidence of subjects with Grade 3 or higher Gastrointestinal events (nausea, diarrhea, or vomiting) according to CTCAE v5.0
  • 10. Wernicke encephalopathy (WE) events [ Time Frame: Up to 30 days post last dose ]
    Occurrence of confirmed Wernicke encephalopathy events
  • 11. Health-Related Quality of Life (HRQoL) [ Time Frame: Up to 30-day follow-up after last dose visit ]
    To evaluate Health-Related Quality of Life (HRQoL) as measured by the European Organization for Research and Treatment of Cancer Quality of Life C30 (EORTC QLQ-C30)
  • 12. EQ-5D-5L [ Time Frame: Up to 20-day follow-up after last dose visit ]
    To evaluate Patient Reported Outcomes (PRO) as measured by the EQ-5D-5L questionnaire
  • 13. Overall Survival (OS) [ Time Frame: From randomization to the End of Survival Follow-up (approximately 12 months) ]
    Time from randomization to death due to any reason
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

1. Subject is at least 18 years of age at the time of signing the informed consent form
(ICF)

2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0,
1 or 2

3. Subject has diagnosis of primary myelofibrosis (PMF) according to the 2016 World
Health Organization (WHO) criteria, or diagnosis of post-ET or post-PV myelofibrosis
according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology
report

4. Subject has a DIPSS Risk score of Intermediate-2 or High

5. Subject has a measurable splenomegaly during the screening period as demonstrated by
spleen volume of ≥ 450 cm3 by MRI or CT-scan and by palpable spleen measuring ≥ 5 cm
below the left costal margin

6. Subject has a measurable total symptoms score (≥ 1) as measured by the Myelofibrosis
Symptom Assessment Form (MFSAF)

7. Subject has been previously exposed to ruxolitinib, and must meet at least one of the
following criteria (a and/or b)

1. Treatment with ruxolitinib for ≥ 3 months with inadequate efficacy response
(refractory) defined as < 10% spleen volume reduction by MRI or < 30% decrease from baseline in spleen size by palpation or regrowth (relapsed) to these parameters following an initial response 2. Treatment with ruxolitinib for ≥ 28 days complicated by any of the following (intolerant): - Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months) or - Grade ≥ 3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while on treatment with ruxolitinib 8. Subject must have treatment-related toxicities from prior therapy resolved to Grade 1 or pretreatment baseline before start of last therapy prior to randomization 9. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted 10. Subject is willing and able to adhere to the study visit schedule and other protocol requirements 11. A female of childbearing potential (FCBP) must: 1. Have 2 negative pregnancy tests as verified by the Investigator during screening prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence* from heterosexual contact. 2. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use and be able to comply with highly effective contraception** without interruption, -14 days prior to starting investigational product, during the study treatment (including dose interruptions), and for 30 days after discontinuation of study treatment. Note: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). 12. A male subject must: Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 30 days following investigational product discontinuation, or longer if required for each compound and/or by local regulations, even if he has undergone a successful vasectomy Exclusion Criteria: 1. Any of the following laboratory abnormalities: 1. Platelets < 50 x 109/L 2. Absolute neutrophil count (ANC) 100 x 109/L

4. Myeloblasts ≥ 5 % in peripheral blood

5. Estimated glomerular filtration rate 1.5 x upper limit of normal (ULN)

7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper
limit of normal (ULN)

8. Total bilirubin > 1.5 x ULN, subject's total bilirubin between 1.5 - 3.0 x ULN
are eligible if the direct bilirubin fraction is
10 mg/day prednisone or equivalent. Subjects who have had prior exposure to
hydroxyurea (eg, Hydrea) in the past may be enrolled into the study as long as it has
not been administered within 14 days prior to randomization

10. Subject has received ruxolitinib within 14 days prior to randomization

11. Subject with previous exposure to Janus kinase (JAK) inhibitor(s) other than
ruxolitinib treatment

12. Subject on treatment with aspirin with doses > 150 mg daily

13. Subject with major surgery within 28 days prior to randomization

14. Subject with diagnosis of chronic liver disease (eg, chronic alcoholic liver disease,
autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis,
hemochromatosis, non-alcoholic steatohepatitis)

15. Subject with prior malignancy other than the disease under study unless the subject
has not required treatment for the malignancy for at least 3 years prior to
randomization. However, subject with the following history/concurrent conditions
provided successfully treated may enroll: non-invasive skin cancer, in situ cervical
cancer, carcinoma in situ of the breast, incidental histologic finding of prostate
cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system),
or is free of disease and on hormonal treatment only

16. Subject with uncontrolled congestive heart failure (New York Heart Association
Classification 3 or 4)

17. Subject with known human immunodeficiency virus (HIV), known active infectious
Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC)

18. Subject with serious active infection

19. Subject with presence of any significant gastric or other disorder that would inhibit
absorption of oral medication

20. Subject is unable to swallow capsule

21. Subject with any significant medical condition, laboratory abnormality, or psychiatric
illness that would prevent the subject from participating in the study

22. Subject has any condition including the presence of laboratory abnormalities, which
places the subject at unacceptable risk if he/she were to participate in the study

23. Subject has any condition that confounds the ability to interpret data from the study

24. Subject with participation in any study of an investigational agent (drug, biologic,
device) within 30 days prior to randomization

25. Subject with a life expectancy of less than 6 months

Contacts and Locations
Contacts

Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations
Show 104 Study Locations
Sponsors and Collaborators

Celgene

Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Investigators

Study Director: Daniels Buglio, MD Celgene Corporation

More Information
  • Responsible Party: Celgene
  • ClinicalTrials.gov Identifier: NCT03952039 History of Changes
  • Other Study ID Numbers: FEDR-MF-002, U1111-1223-2962, 2018-003411-21
  • First Posted: May 16, 2019 Key Record Dates
  • Last Update Posted: April 7, 2020
  • Last Verified: April 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Yes
  • Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Supporting Materials: Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code
  • Time Frame: See Plan Description
  • Access Criteria: See Plan Description
  • URL: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: MF
    myeloproliferative neoplasms
    myelofibrosis
    PMF
    Post-Polycythemia Vera
    post-ET MF
    Post-Essential Thrombocythemia Myelofibrosis
    MPN
    post-PV
  • Additional relevant MeSH terms: Polycythemia Vera
    Primary Myelofibrosis
    Polycythemia
    Thrombocytosis
    Thrombocythemia, Essential